Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 314

Results For "C"

10164 News Found

Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr
News | October 25, 2024

Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr

Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024


Thyrocare Technologies posts Q2 FY25 consolidated net profit at of Rs. 26.67 Cr
News | October 25, 2024

Thyrocare Technologies posts Q2 FY25 consolidated net profit at of Rs. 26.67 Cr

Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024


Jagsonpal Pharmaceuticals Q2 FY25 net profit up at Rs. 11.45 Cr
News | October 25, 2024

Jagsonpal Pharmaceuticals Q2 FY25 net profit up at Rs. 11.45 Cr

Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024


Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr
News | October 25, 2024

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024


Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs
Biotech | October 23, 2024

Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC


Jubilant Ingrevia appoints Vijay Srivastava as Chief of Operations
People | October 23, 2024

Jubilant Ingrevia appoints Vijay Srivastava as Chief of Operations

He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates


Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr
News | October 23, 2024

Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr

Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024


European Food Safety Authority confirms safety of silica as food additive
News | October 23, 2024

European Food Safety Authority confirms safety of silica as food additive

Silica is a proven and highly effective anti-caking agent that has been used for decades


Sumitomo Corporation entered into contract with Revorf
News | October 23, 2024

Sumitomo Corporation entered into contract with Revorf

Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies